Prohost BioTechnology
Biotechnology Research and Investment

PROHOST LETTER # 360 APRIL 14, 2014

The Indiscriminate slaughter Of The Biotech Sector

If Gilead Is The Reason Of the massacre

So Let's talk About Gilead

The slaughter of the biotech sector i aid to be caused by Gilead (GILD), the firm that's offering the first HCV drug to wipe out hepatitis C virus. Revenue from GILD's drug Sovaldi are pouring into the firm's coffers. Specialists are prescribing Sovaldi not because they love Gilead, but because they love their patients and do not like to see them develop liver cirrhosis, have liver transplantation and liver cancer. The complications of HCV infection are what's breaking the country' financial back, not the $83,000 dollars - a price to be paid to save the cost of the complications that amounts to millions of dollars.

WSJ said: Gilead's Sovaldi is expected to sell for $5B in first year. It is on track to be among the biggest sales ever for the first year of a newly approved drug. Solvadi could make up to $5B in U.S. sales this year if current prescription patterns hold.

The talk is about Sovaldi only, not the all-oral combination that will be approved a few month from now, which is expected to generate double the amount Sovaldi is on the road to generate this year,

Who is calculating?

Why talking about the price of a pill, not the cost of the whole treatment, which takes only three month from beginning to end?

What's going on now in the HCV management is spending on drugs that are no cures; that do not stop the progression of liver damage; do not prevent liver cirrhosis; do not prevent infection of the transplanted livers in case patient are too late to avoid liver transplantation.

The current treatments and intervention cost millions and do nothing.

Indeed, studies have demonstrated that Gilead's all-oral combination prevents the HCV from infecting the transplanted liver.

Newly announced data demonstrate that seventy percent of patients with genotype 1-HCV infection and with **recurrent HCV infection following liver transplantation who received up to 24 weeks of therapy with Sovaldi plus RBV achieved sustained viral response (SVR12).**

There were no deaths, graft losses or episodes of organ rejection among post-liver transplantation patients, and no drug-drug interactions were reported between Sovaldi and immunosuppressive agents.

Another compassionate access study evaluated Sovaldi therapy among 104 post-transplant patients with **severe recurrent HCV, including fibrosing cholestatic hepatitis**, **who had exhausted all other treatment options and received pre-approval access to Sovaldi via Gilead's compassionate use program.**

The results were stunning in this untreatable category of patients. Overall, 62 percent of patients achieved SVR12. The patients included in these analyses are historically among the most difficult to cure and many have had no appropriate treatment options until now.

These results had never been seen before. Those who are talking about boycotting Sovaldi do not mention them and it seems that nobody in their families has had advanced HCV infection and complications.

They talk only about the high cost of Sovaldi.

Are they serious? Is Sovaldi the first drug to be costly? There are drugs on the market that cost over $200,000 and nobody talked. There is an HCV combination on the market that sells for almost double Sovaldi's cost? Why nobody talked before or even talking now about these expensive drugs? If those people are serious, then why don't they sit around a table and discuss every ingle issue that really contributes to "breaking the country's back"? They will find a lot of issues. The problem is that they will never act.

OUR PORTFOLIOS

PORTFOLIO #1

FIRMS & SYMBOLS	Price & Date Stocks Picked	4/11/14 Price	Market Cap.	Dec 2014 Targets	Dec. 2016 Targets	DECISIONS
TOP-TIER FIRMS. GENERAL DRUG DEVELOPING FIRMS						
GILEAD (GILD)	$20.75 On 3/18/11	$66.03	101.6 B	$100	$200	TARGETS UNCHANGED WE ACCUMULATE.
AMGEN (AMGN)	$52.94 On 3/18/11	$111. 94	84.52 B	$150	$200	TARGETS UNCHANGED We ACCUMULATE
REGENER. (REGN)	$38.81 On 03/18/11	$288.36	26.59 B	$350	$500	TARGETS UNCHANGED
VERTEX (VRTX)	$44.39 On 03/18/11	$63.06	14.87 B	$85	$160	TARGETS UNCHANGED
ILLUMINA (ILMN)	$62.11 On 03/18/11	$139.99	17.96 B	$200	$500	TARGETS UNCHANGED
JAZZ (JAZZ)	$29.2 On 03/18/11	$128.614	7.47 B	$200	$250	TARGETS UNCHANGED
CANCER COMPANIES. EACH WITH ONE MARKETED PRODUCT						
PHARMAC. (PCYC)	$15.25 On 11/5/11	$86.11	6.44 B	$100	$200	2014 TARGET LOWERED FROM $110 to $100
INCYTE (INCY)	$14.29 On 03/18/11	$46.25	7.66 B	$75.	$120	TARGETS UNCHANGED
IMMUNOG (IMGN)	$8.50 On 03/18/11	$12.90	1.11 B	$25	$55 R	TARGETS UNCHANGED
ARIAD ARIA)	$6.40 On 03/18/11	$7.14	1.33 B	$14	$28	TARGETS UNCHANGED
Seattle Gen. (SGEN)	$14.28 On 03/18/11	$37.15	5.57 B	$70	$120	TARGETS UNCHANGED
DIVERSIFIED DRUG DEVELOPER						
Theravance (THRX)	$24.03 On 03/12/13	$27.99	3.13 B	$50	$70	TARGETS UNCHANGED
ANTISENSE PRODUCTS						
ISIS (ISIS)	$8.62 On 03/18/11	$42.07	4.93 B	$55	$125	TARGET UNCHANGED
ALNYLAM (ALNY)	$10.80 On 01/25/12	$63.97	4.09 B	$80	$150	2014 TARGET LOWERED TO $70
SAREPTA (SRPT)	$28.33 On 11/21/12	$22.99	868 M	$40	$60	TARGETS UNCHANGED
SANGAMO (SGMO)	$7.19 On 3/18/11	$18.24	$1.14 B	$22	$35	TARGETS UNCHANGED When target was reached we sold some stock
PLEURISTEM (PSTI): NOT YET OFFICIALLY CONFIRMED AS A PICK.						

Explanations On Wednesday Prohost Letter

Prohost BioTechnology
Biotechnology Research and Investment

PORTFOLIO #2

Firms and Symbols	Date Picked and Price	Price 4/11/14	Market Cap	1st Target	2016 Target	Observations and Decisions
			NEWELY PICKED FIRMS			
PORTOLA (PTLA)	$26.65 On 2/22/2014	$20.78	852.6 M	$40	$80	TARGETS UNCHANGED
NEKTAR	$12.84 On 1/27/14	$10.53	1.56 B	$!6	$35	TARGETS UNCHANGED
ENANTA (ENTA)	$20.75 On 11/25/13	$33.37	614.6 M	$45	$55	TARGETS UNCHANGED AT THIS TIME
BIOCRYST (BCRX)	$9.40 On Jan. 8 2014	$8.91	529.11 M	$18	$32	TARGETS UNCHANGED. EXPECTED APPROVAL
COMPUGEN CGEN	$10 On Jan. 8, 2014	$9.49	414 M	$18	$28	TARGETS UNCHANGED LONG TERM BUT CAN HAVE A SUDDEN RALLY The 2014 target mean that we are not selling the stock before reaching our target
			DEVELOPMENT STAGE CANCER COMPANIES			
EXELXIS (EXEL)	$11.35 On 3/18/11	$3.37	635.6 M	$16	$35	TARGETS LOWERED TO $10
ARRAY (ARRY)	$3.00 On 3/18/11	$3.83	$480.50.M	$12	$15	TARGETS UNCHANGED
ENDOCYTE (ECYT)	$17.45 On 8/05/13	$19,58	708.40 M	$40	$60	Great news TARGETS UNCHANGED
SUNESIS (SNSS)	$2.48 On 3/29/12	$5.54	332.92 M	$12	$20	1st TARGET RAISED RECENTLY 2016 TARGET ALSO RAISED RECENTLY
			GENERAL DRUG DEVELOPERS AND DRUG DELIVERY			
XOMA (XOMA)	$4.51 On 3/18/11	$4.14	441.74.05 M	$12	$22	TARGETS LOWERED TO $10
HALOZYME (HALO)	$6.57 On 3/25/13	$7.42	845.14 M	$25	$35	TARGETS LOWERED TO $12
			THERAPEUTIC VACCINES FOR CANCER AND OTHER DISEASES			
CELLDEX (CLDX)	$25.65 On 11/11/13	$14.02	$1.25 B	$20	-------	WARNING: 1st target lowered to $20 We SOLD most of the stock and kept some stock to accumulate if and when concrete data would surface. WE BUY SOME MORE STOCK AS PRICE IS BELOW TARGET NOW.
DENDREON (DNDN)	$7.56 On 1/3/12	$2.70	414.08 M	$6-$7	$9	TARGETS UNCHANGED
AGENUS (AGEN)	$5.64 On 3/18/11.	$2,70	$167.87 M	$10	$30	TARGETS UNCHANGED. WE ACCUMULATE SLOWLY
			PRENATAL DIAGNOSIS FIRMS			
SEQUENOM (SQNM)	$5.92 On 3/18/11	$2.45	286.09. M	$4	$6	ILLUMINA'S HAS BECOME DANGEROUS FOR THIS FIRM. ACQUISITION IS A REMOTE POSSIBILITY. WE SELL NOW AND BUY ARRY OR AGEN

WE WILL ASSESS INDIVIDUAL STOCKS IN THE NEXT TWO DAYS
WE BELIEVE THERE WERE NO BALLOONS AMONG OUR PICKS
WE BELIEVE THE TORM IS ONE OF THOSE THAT OCCUR IN TEACUPS

NOTES

FORWARD-LOOKING: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our 'opinions' and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal.